SV Health Investors Secures £25M from British Patient Capital for Dementia Fund
Deal News | Mar 20, 2025 | SV Health Investors, LLC
British Patient Capital, a subsidiary of the British Business Bank, has committed £25 million to the Dementia Discovery Fund 2 (DDF-2), managed by SV Health Investors. This investment aims to support the development of novel therapeutics for dementia, a prevalent global issue affecting 55 million people. The Dementia Discovery Fund focuses on leveraging experienced investment professionals and strategic industry partners to nurture companies developing high-impact dementia treatments. With this commitment, the fund has achieved its target of $250 million, intending to progress the advances in neurodegenerative disease treatments. SV Health Investors aims to continue its strategy to invest in and support biotech companies with promising dementia treatments, promising both patient advancements and strong financial returns. British Patient Capital's investment highlights the UK's leadership in life sciences and the need for long-term capital in R&D-intensive sectors to commercialize breakthrough research.
Sectors
- Venture Capital
- Healthcare
- Biotechnology
- Life Sciences
Geography
- United Kingdom – British Patient Capital, based in the UK, is making significant investments in the nation's life sciences sector.
- United States – The Dementia Discovery Fund operates with offices in London and Boston, indicating transatlantic investment activity.
Industry
- Venture Capital – The article discusses the investment by British Patient Capital in the Dementia Discovery Fund, a venture capital fund.
- Healthcare – The Dementia Discovery Fund invests in companies developing therapeutics for dementia.
- Biotechnology – The fund focuses on biotech companies that create novel therapeutics for dementia.
- Life Sciences – The article highlights the UK's leadership position in life sciences, particularly in neurodegenerative disease research.
Financials
- £25 million – The commitment made by British Patient Capital to Dementia Discovery Fund 2.
- $250 million – The target raise achieved by the Dementia Discovery Fund 2.
- $2.8 trillion – The expected global costs associated with dementia by 2030.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| SV Health Investors | Fund Manager | Company | Manages the Dementia Discovery Fund, which invests in dementia therapeutic development. |
| British Patient Capital | Investor | Company | A commercial subsidiary of the British Business Bank investing in high-potential UK life sciences companies. |
| Dementia Discovery Fund 2 (DDF-2) | Fund | Company | A venture capital fund dedicated to investing in dementia treatment development. |
| British Business Bank | Parent Company | Company | The economic development bank of the UK government and parent to British Patient Capital. |
| Christian Jung | Partner | Person | A Partner at SV Health Investors discussing the impact of the investment. |
| Christine Hockley | Managing Director, Funds | Person | Managing Director at British Patient Capital reflecting on the investment. |
| Mark Andrews | Investment Director, Life Sciences | Person | Investment Director at British Patient Capital discussing the strategic importance of the investment. |
| Various pharmaceutical companies and non-profits | Limited Partners | Company/Organization | Includes firms like Biogen, Bristol Myers Squibb, Eli Lilly, and organizations like Alzheimer's Research UK contributing to DDF. |